Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

NEXT STORY
Updated – Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021
PREV STORY
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021

author_avatar
NASDAQ Market News

Biohit GastroPanel® accurately predicted the progression of atrophic gastritis and its transition to gastric cancer in a European multicenter trial

Biohit Oyj press release 05.09.2018 klo 10.10 local time (EEST) A Dutch research group ...

author_avatar
NASDAQ Market News

Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation

– 91% CR+CRi/CRp Rate in Ivosidenib-treated Patients with De Novo AML and 53% in Ivosidenib-treated ...

author_avatar
NASDAQ Market News